Human Genome Epidemiology Literature Finder
Records 1 - 8 (of 8 Records) |
Query Trace: Cough and EGFR[original query] |
---|
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Sep 31 (27): 3327-34. Sequist Lecia V, Yang James Chih-Hsin, Yamamoto Nobuyuki, O'Byrne Kenneth, Hirsh Vera, Mok Tony, Geater Sarayut Lucien, Orlov Sergey, Tsai Chun-Ming, Boyer Michael, Su Wu-Chou, Bennouna Jaafar, Kato Terufumi, Gorbunova Vera, Lee Ki Hyeong, Shah Riyaz, Massey Dan, Zazulina Victoria, Shahidi Mehdi, Schuler Mart |
Clinical Features and Gene Mutations of Lung Cancer Patients 30 Years of Age or Younger. PloS one 2015 10 (9): e0136659. Wang Yuehong, Chen Junjun, Ding Wei, Yan Bing, Gao Qiqi, Zhou Jianyi |
Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study. BMC cancer 2018 Mar 18 (1): 333. Brueckl Wolfgang M, Achenbach H Jost, Ficker Joachim H, Schuette Wolfga |
Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. Cancer research and treatment 2019 Jul . Ahn Myung-Ju, Han Ji-Youn, Kim Dong-Wan, Cho Byoung Chul, Kang Jin-Hyoung, Kim Sang-We, Yang James Chih-Hsin, Mitsudomi Tetsuya, Lee Jong Se |
Successful treatment of a lung adenocarcinoma patient with a novel EGFR exon 20-ins mutation with afatinib: A case report. Medicine 2019 1 98 (1): e13890. Cai Yangyang, Wang Xu, Guo Ye, Sun Chao, Xu Yinghui, Qiu Shi, Ma Kew |
First-in-Human Phase 1 Study of ES-072, an Oral Mutant-Selective EGFR T790M Inhibitor, in Non-Small-Cell Lung Cancer. Clinical lung cancer 2020 8 21 (6): 509-519.e1. Zheng Jing, Shen Lisha, Jiang Nan, Zhu Yanping, Wu Lihua, Cao He, Sun Wenjia, Zhou Jianya, Zhou Jianyi |
De Novo mutation in Epidermal growth factor receptor (EGFR)-D761Y responding to third generation tyrosine kinase inhibitor Osimertinib: A case report. Medicine 2022 7 101 (29): e29332. Ding Yingying, Dong Hongliang, Li YongCheng, Liu Lei, Cai Ying, Wang Ying, Tian Shengya, Dai Chengt |
Phase I Trial of a Third Generation EGFR Mutant-Selective Inhibitor (D-0316) in Patients with Advanced Non-Small Cell Lung Cancer. The oncologist 2022 3 27 (3): 163-e213. Jian Hong, Wang Kai, Cheng Ying, Ding Lieming, Wang Yang, Shi Zhe, Zhang Ling, Wang Yaolin, Lu Sh |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: